Article
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.
The Lancet. Oncology - 1 Jan 2023
Ascierto Paolo A, Stroyakovskiy Daniil, Gogas Helen, Robert Caroline, Lewis Karl, Protsenko Svetlana, Pereira Rodrigo P, Eigentler Thomas, Rutkowski Piotr, Demidov Lev, Zhukova Natalia, Schachter Jacob, Yan Yibing, Caro Ivor, Hertig Christian, Xue Cloris, Kusters Lieke, McArthur Grant A, Gutzmer Ralf
Abstract excerpt
BACKGROUND: Primary analysis of the phase 3 IMspire150 study showed improved investigator-assessed progression-free survival with first-line atezolizumab, vemurafenib, and cobimetinib (atezolizumab group) versus placebo, vemurafenib, and cobimetinib (control group) in patients with BRAFV600 mutation-positive melanoma. With a median follow-up of 18·9 months (IQR 10·4-23·8) at the primary analysis, overall survival...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.